



THERAPEUTIC APPROACHES AND CHALLENGES IN COVID-19 MANAGEMENT: A PRAGMATIC REVIEW

¹Sibi S, ²Pugazh Gowrishankar, ³Diwakaran, ^{4*}Vijai Krishna V and ⁵Sujitha K

¹PERI College of Pharmacy, Chennai – 48, Tamil Nadu, India

²PERI Institute of Technology, Chennai - 48, Tamil Nadu, India

³PERI College of Arts and Science, Chennai - 48, Tamil Nadu, India

^{4*}PERI College of Physiotherapy, Chennai - 48, Tamil Nadu, India

⁵PERI College of Nursing, Chennai - 48, Tamil Nadu, India

Article History: Received 18th September 2025; Accepted 27th October 2025; Published 15th November 2025

ABSTRACT

The COVID-19 pandemic has posed unprecedented challenges to global healthcare systems, necessitating rapid development and implementation of effective therapeutic strategies. This pragmatic review evaluates current approaches to COVID-19 management, highlights associated challenges, and provides evidence-based recommendations. Therapeutic interventions, including antiviral agents, corticosteroids, monoclonal antibodies, immunomodulators, and supportive care, have demonstrated varying efficacy depending on disease severity and patient comorbidities. Major challenges include drug availability, evolving viral variants, adverse effects, and disparities in healthcare access. Additionally, uncertainties surrounding optimal timing, dosage, and combination therapies complicate clinical decision-making. By synthesizing the latest evidence from clinical trials, guidelines, and real-world studies, this review identifies key gaps in knowledge and emphasizes the importance of individualized patient care. Recommendations focus on early diagnosis, stratified therapeutic approaches, monitoring for complications, and integration of novel therapies as data emerge. This review aims to guide clinicians, policymakers, and researchers in optimizing COVID-19 management and preparing for future infectious disease threats.

Keywords: COVID-19, SARS-CoV-2, Pragmatic approach, Systemic immunotherapy, Remdesivir, Dexamethasone.

INTRODUCTION

The outbreak of COVID-19, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has evolved into one of the most significant global health crises in modern history. Declared a pandemic by the World Health Organization (WHO) in March 2020, the disease has challenged healthcare systems worldwide with unprecedented caseloads, resource shortages, and high mortality rates. In India, the devastating impact of the second wave underscored systemic vulnerabilities, including limited hospital capacity, oxygen shortages, and unequal access to essential medicines. While vaccines and evidence-based treatments have shown promise in reducing severe disease and mortality, clinical management remains inconsistent, particularly in resource-constrained settings.

A multitude of untested or marginal therapies have been prescribed, further complicating treatment protocols and patient outcomes. Simultaneously, patients with chronic inflammatory skin and immune-mediated disorders receiving systemic immunotherapy face unique risks, necessitating cautious therapeutic decisions. This review adopts a pragmatic perspective by consolidating current evidence on therapeutic strategies, evaluating proven and unproven treatments, and emphasizing home-based care for mild cases. By critically analyzing existing approaches and challenges, it aims to provide practical recommendations for clinicians,

This literature review synthesizes recent evidence on pragmatic COVID-19 management, focusing on therapeutic strategies, immunomodulation, antivirals, outpatient care,

* Corresponding Author: Vijai Krishna V, PERI College of Arts and Science, Chennai – 48, Tamil Nadu, India Email: publications@peri.ac.in

vaccines, and special-population considerations. The selected studies (Li, Hilgenfeld *et al* (2023)) provide a broad and current foundation for clinical recommendations and identify gaps for future research. Comprehensive reviews highlight the rapid evolution of COVID-19 therapeutics, from repurposed small molecules to targeted antivirals and host-directed therapies. Li *et al.* provide a broad overview of therapeutic progress and lessons learned during the pandemic, emphasizing the value of rapid evidence synthesis and adaptive clinical trial designs. They stress that treatment strategies must balance antiviral activity with host immune modulation to reduce mortality and healthcare burden. Focosi *et al.* similarly summarize available therapeutics and note shifting roles for older agents (e.g., remdesivir) versus newly authorized oral antivirals and monoclonal antibodies as variants emerge Abdelrahman, Li, Wang (2021). Multiple meta-analyses and real-world studies examine antivirals' impact on mortality and hospitalization. Systematic reviews on newer agents such as azvudine indicate potential mortality benefits in some cohorts but call for larger randomized data to confirm effects and safety Meng *et al* (2022). Paxlovid (nirmatrelvir-ritonavir) has consistent evidence for reducing progression when given early; Wang *et al.* summarize meta-analytic evidence supporting its outpatient use J. Meng *et al* (2024). Real-world evaluations of remdesivir show mixed results while some functional outcome improvements are reported in post-hospitalized cohorts, benefits depend heavily on timing and patient severity Lu, W *et al* (2024). Reviews focused on outpatient randomized trials emphasize that early antiviral therapy remains the most promising approach to prevent hospitalization, but cautions regarding resistance and access remain Li, J *et al* (2024).

Corticosteroids (notably dexamethasone) and other immunomodulators are central for patients with hypoxemic respiratory failure. Meta-analytic evidence supports glucocorticoid use in severe disease to reduce mortality, yet optimal timing and dose require context-specific decisions Lu, W *et al* (2024). Mesenchymal stem cell (MSC) therapy and other advanced immunotherapies are evaluated in randomized and pooled analyses; Lu *et al.* report favorable signals for MSCs in select trials but call for standardized protocols and long-term safety evaluation Niimoto, T *et al* (2024). Ju *et al.*'s meta-analysis on immunomodulators underscores heterogeneity across studies, indicating that subgroup analyses (by severity, timing, concomitant therapy) are critical to interpret pooled results Kimura, S *et al* (2025). Several systematic reviews address therapies that generated early enthusiasm but later produced weak or conflicting evidence. Ivermectin and hydroxychloroquine, for example, have not shown consistent clinical benefit in high-quality trials, and systematic reviews recommend against routine use outside clinical studies Raphael, J., Le, B., Singh, S (2025). The literature cautions that adopting unproven therapies beyond the risks to patients diverts scarce resources and complicates public messaging Lu, W *et al* (2024). Vaccination remains the cornerstone of

pandemic control. Reviews on vaccine delivery emphasize not only clinical efficacy but also logistics, equity, and systems for mass rollout; lessons learned in delivery strategies can inform future pandemic responses and booster campaigns Li, J *et al* (2024). Studies highlight the need for tailored approaches to reach underserved populations and for integrating vaccination with other public-health measures to reduce severe disease and system strain Kimura, S *et al* (2025).

Several systematic reviews advocate pragmatic outpatient pathways to triage and manage mild-to-moderate cases at home, reserving hospital resources for severely ill patients Niimoto, T *et al* (2024). Reviews of outpatient randomized trials show that early antiviral or monoclonal-based interventions can substantially reduce progression risk when accessible; however, equitable distribution and rapid diagnostic access are practical barriers Wang, Y *et al* (2024). The pandemic raised complex questions about continuing immunotherapy for patients with immune-mediated diseases or cancer. Case reports and cohort analyses document events such as cytokine release or increased adverse events in patients receiving immune-checkpoint inhibitors who contract COVID-19 Kimura, S *et al* (2025) and Ju, J. *et al* (2025). These studies recommend individualized risk-benefit assessments and close monitoring rather than blanket cessation of immunotherapy, with particular caution for severe infection risk and vaccine response variability Niimoto, T *et al* (2024).

A methodological review found variability in the quality of COVID-19 systematic reviews, reflecting rapid publication pressures and heterogeneity in outcome measures and trial designs Li, J *et al* (2024). McDermott *et al.* highlight the need for rigorous meta-analytic methods, transparent reporting, and living systematic reviews to keep guidance current as new data emerge Raphael, J., Le, B., Singh, S (2025). Systematic reviews of case reports on myocarditis and other rare complications illustrate the diversity of COVID-19 presentations and the need for tailored treatment strategies, including immunomodulation and supportive care for organ-specific complications Lu, W *et al* (2024). Together, these studies support a pragmatic, tiered approach: prioritize vaccination and prevention; use early, evidence-based antivirals or monoclonal therapies in high-risk outpatients; apply corticosteroids and selected immunomodulators in hypoxemic hospitalized patients; and maintain individualized management for immunocompromised or oncology patients. Persistent gaps include (1) high-quality randomized data for newer antivirals and combination regimens against evolving variants, (2) standardized protocols for immunotherapies and MSCs, (3) equitable access and implementation research for outpatient therapeutics and vaccination programs, and (4) living syntheses to rapidly incorporate variant-specific efficacy. Addressing these gaps will

strengthen the pragmatic framework for managing COVID-19 across settings.

MATERIALS AND METHODS

Study Design

This work is designed as a narrative review with a pragmatic orientation, focusing on therapeutic approaches, challenges, and recommendations for COVID-19 management. The methodology emphasizes the consolidation of evidence from peer-reviewed journals, systematic reviews, meta-analyses, and real-world cohort studies published between 2020 and 2025. The objective was not only to evaluate treatment efficacy but also to identify feasible strategies that can be implemented in diverse healthcare settings, particularly in resource-limited environments.

Data Sources

A comprehensive literature search was carried out using major databases, including PubMed, Scopus, Web of Science, and IEEE Xplore. In addition, official reports from the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and relevant governmental health agencies were consulted to ensure inclusion of global perspectives and guideline updates.

Search Strategy and Keywords

The search employed a combination of medical subject headings (MeSH) and free-text keywords such as “COVID-

19,” “SARS-CoV-2,” “therapeutic strategies,” “immunotherapy,” “antivirals,” “dexamethasone,” “vaccination,” “pragmatic management,” and “systematic review.” Boolean operators (AND/OR) were used to refine the search and include studies specifically addressing treatment outcomes, vaccination strategies, and pragmatic management approaches.

Inclusion and Exclusion Criteria

Studies were included if they (a) reported therapeutic interventions for COVID-19, (b) evaluated clinical outcomes such as hospitalization, mortality, or adverse events, and (c) were peer-reviewed journal articles, systematic reviews, or meta-analyses. Articles were excluded if they (a) were not in English, (b) were preprints without peer review, or (c) focused solely on basic virology without clinical or therapeutic implications.

Data Extraction and Analysis

Relevant information, including study design, patient population, type of intervention, outcomes, and limitations, was extracted from each paper. To ensure consistency, two independent reviewers screened and cross-checked the selected articles. Findings were then synthesized under thematic categories such as antiviral therapy, immunomodulators, unproven treatments, vaccination strategies, outpatient management, and special populations. Qualitative synthesis was prioritized due to heterogeneity in study designs and outcome measures.




Figure 1. Pragmatic Approach for COVID-19.

RESULT AND DISCUSSION

The analysis of current literature reveals that early, evidence-based interventions significantly influence clinical outcomes in COVID-19 patients. Antiviral agents, including remdesivir, azvudine, and Paxlovid (nirmatrelvir–ritonavir), demonstrated variable efficacy depending on timing, patient risk factors, and disease severity. Early outpatient administration of Paxlovid

reduced hospitalization rates and progression to severe disease, confirming its role as a frontline therapy for high-risk individuals Li, J *et al* (2024). Remdesivir showed functional improvement in select cohorts but was less consistently effective in real-world, post-hospitalization studies. Novel therapies, such as mesenchymal stem cell (MSC) therapy, showed potential benefit in severe COVID-19 but require further standardization and long-term safety evaluation Raphael, J., Le, B., Singh, S (2025).




Figure 2. COVID -19 Management Therapeutic Approaches, Challenges, and Recommendations.

Corticosteroids, particularly dexamethasone, consistently reduced mortality in hypoxemic and severely ill patients. Optimal outcomes were closely linked to timing and dosage, highlighting the need for individualized treatment plans. Additional immunomodulators, including monoclonal antibodies and targeted immunotherapies, showed promising results in select populations but required careful monitoring to mitigate adverse events, especially among patients receiving systemic immunotherapy. Pragmatic home-based care for mild to moderate COVID-19 cases proved effective in reducing healthcare system burden. Systematic reviews emphasize early triage, risk stratification, and timely initiation of outpatient antiviral or monoclonal therapies. Real-world evidence suggests that accessible, structured home-care protocols can prevent unnecessary hospitalization while ensuring patient safety. Vaccination remained the cornerstone of pandemic management. Studies highlight that equitable vaccine distribution, booster administration, and integration with public-health strategies significantly reduce severe disease and mortality. Lessons from mass vaccination campaigns indicate that logistical planning, community outreach, and targeted interventions are essential to maximize coverage and mitigate disparities (Figure 1&2).

Patients receiving systemic immunotherapy or cancer treatment presented unique challenges. Evidence indicates that therapy continuation may be feasible under close monitoring, with individualized risk–benefit assessments. Early antiviral intervention and vaccination are particularly important for these populations to reduce morbidity and prevent prolonged viral persistence. Therapies such as ivermectin and hydroxychloroquine were not supported by high-quality clinical evidence. Use of such unproven agents carries potential risks, including adverse events, resource diversion, and misinformation propagation, underscoring the importance of evidence-based guidance. Several challenges emerged from the review. Heterogeneity in study designs and outcomes limited cross-study comparability. Resource constraints, misinformation, and inconsistent implementation of public-health measures

impeded optimal pandemic management. Persistent gaps include the need for high-quality randomized data on emerging antivirals, standardized immunotherapy protocols, and scalable outpatient treatment pathways.

CONCLUSION

This review highlights the importance of a pragmatic, evidence-based approach to COVID-19 management. Early antiviral therapy, appropriate use of corticosteroids and immunomodulators, vaccination, and structured home-based care collectively form the cornerstone of effective pandemic control. For immunocompromised and oncology patients, individualized risk–benefit assessments are essential, allowing safe continuation of systemic immunotherapy under close monitoring. The review underscores that unproven therapies, such as ivermectin and hydroxychloroquine, lack clinical efficacy and may complicate patient care and public-health messaging. Overall, a tiered management strategy prioritizing prevention, early intervention, and tailored therapeutic decisions can reduce morbidity, optimize healthcare resource utilization, and improve patient outcomes across diverse healthcare settings.

ACKNOWLEDGMENT

The authors express sincere thanks to the head of the Department of Zoology, Madras University for the facilities provided to carry out this research work.

CONFLICT OF INTERESTS

The authors declare no conflict of interest

ETHICS APPROVAL

Since this study is a review based on secondary sources and publicly available literature, no direct human or animal subjects were involved. Ethical clearance was therefore not required.

FUNDING

This study received no specific funding from public, commercial, or not-for-profit funding agencies.

AI TOOL DECLARATION

The authors declares that no AI and related tools are used to write the scientific content of this manuscript.

DATA AVAILABILITY

Data will be available on request

REFERENCES

- Li, G., Hilgenfeld, R., Whitley, R., & De Clercq, E. (2023). Therapeutic strategies for COVID-19: Progress and lessons learned. *Nature Reviews Drug Discovery*, 22(6), 449–475.
- Abdelrahman, Z., Li, H., & Wang, H. (2021). Evaluation of the current therapeutic approaches for COVID-19: A systematic review and meta-analysis. *Frontiers in Pharmacology*, 12, 607408.
- Meng, J., Ma, X., Zhou, T., Zhang, Y., & Zhao, Y. (2022). A review of potential therapeutic strategies for COVID-19. *Viruses*, 14(11), 2346.
- Meng, J., Xie, H., & Wang, L. (2024). Effectiveness of azvudine in reducing mortality of COVID-19 patients: A systematic review and meta-analysis. *Virology Journal*, 21, 46.
- Lu, W., Yan, L., & Tang, X. (2024). Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. *Journal of Translational Medicine*, 22, 550.
- Li, J., Chen, Y., & Ye, H. (2024). Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children: A retrospective cohort study. *BMC Infectious Diseases*, 24, 794.
- Niimoto, T., Todaka, T., & Kimura, S. (2024). Cytokine release syndrome following COVID-19 infection during treatment with nivolumab for cancer of esophagogastric junction carcinoma: A case report and review. *International Journal of Emergency Medicine*, 17, 106.
- Kimura, S., Katsuya, H., & Nakashima, C. (2025). Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID-19 pandemic. *BMC Immunology*, 26, 33.
- Raphael, J., Le, B., & Singh, S. (2025). Early mortality in patients with cancer and COVID-19 infection treated with immunotherapy. *BMC Cancer*, 25, 922.
- Wang, Y., Yang, Y., Shan, R., Zhao, L., Bai, Y., & Feng, L. (2024). Paxlovid for the treatment of COVID-19: A systematic review and meta-analysis. *The Journal of Infection in Developing Countries*, 18(8), 1169–1178.
- Ju, J., Li, H., Huang, Y., Qing, B., & Sandeep, B. (2025). A meta-analysis of the efficacy and safety of immunomodulators in the treatment of severe COVID-19. *Journal of International Medical Research*, 53(1).

